Breast Cancer | Access and Reimbursement | EU | 2019
MARKET OUTLOOK
The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly) are creating new dynamics in the treatment of metastatic disease, while PARP inhibitor Lynparza (AstraZeneca) is poised to offer treatment for BRCA1/2-mutation-positive tumors. In addition, near-term emerging agents including PI3K inhibitor alpelisib (Novartis), look set to further strengthen the field. This research examines the market access levers and barriers for existing and emerging HR-positive, HER2-negative breast cancer therapies in the top 5 European markets (France, Germany, Italy, Spain, UK) as competition intensifies, the reimbursement environment becomes ever more complex, and healthcare budgets become increasingly constrained.
QUESTIONS ANSWERED
- What role do key brands play in HR-positive, HER2-negative breast cancer treatment in the markets under study? How is their use monitored and restricted?
- How great an uptake advantage is CDK4/6 inhibitor Ibrance’s first-to-market status? What market access strategies help Kisqali and Verzenios to compete?
- Which treatments do surveyed oncologists think perform best on clinical and other attributes? Do interviewed payers consider the overall cost of biomarker-driven prescribing to be justified?
- How can emerging HR+/HER2- breast cancer therapies optimize reimbursement and market access in the top European markets.
PRODUCT DESCRIPTION
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers, examining reimbursement dynamics and evaluating the impact of payer policy on prescribing behavior.
GEOGRAPHY
France, Germany, Italy, Spain, United Kingdom
PRIMARY RESEARCH
- Survey of 250 medical oncologists across the top 5 European markets (50 per country)
- Interviews with 10 payers across the top 5 European markets (2 per country)Key Drugs Covered
KEY DRUGS COVERED
Afinitor, Faslodex, Ibrance, Kisgali, Verzenios, Avastin, Anastrozole, Letrozole, Exemestane, Lynparza, alpelisib
CONTENT HIGHLIGHTS
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Pricing and reimbursement dynamics
- Impact of payer policy and coverage on prescribing
- Market access outlook for emerging therapies
